Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd. American Depositary Shares
Your view on ANL
Overview
What the company does, where it operates, and who runs it.
About Adlai Nortye Ltd. American Depositary Shares
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Yang Lu
- Headquarters
- Ugland House, Grand Cayman, KY
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Yang Lu
- Headquarters
- Ugland House, Grand Cayman, KY
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1.
Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Adlai Nortye Ltd. American Depositary Shares, and the rating behind it. ANL last traded at $15.21; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Adlai Nortye Ltd. American Depositary Shares. Starting points for Adlai Nortye Ltd. American Depositary Shares: EPS -$1.41, beta 1.15 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Adlai Nortye Ltd. American Depositary Shares. Adlai Nortye Ltd. American Depositary Shares does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Adlai Nortye Ltd. American Depositary Shares. Trailing twelve-month EPS for Adlai Nortye Ltd. American Depositary Shares stands at -$1.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Adlai Nortye Ltd. American Depositary Shares. Adlai Nortye Ltd. American Depositary Shares has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Adlai Nortye Ltd. American Depositary Shares valued side by side against its closest peers. Adlai Nortye Ltd. American Depositary Shares is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Adlai Nortye Ltd. American Depositary Shares, and how their positions are changing. At a $807.3M market value, institutional positions materially move Adlai Nortye Ltd. American Depositary Shares's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Adlai Nortye Ltd. American Depositary Shares executives and directors. Shares of Adlai Nortye Ltd. American Depositary Shares have traded between $1.10 and $3.11 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Adlai Nortye Ltd. American Depositary Shares. Adlai Nortye Ltd. American Depositary Shares is a $807.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Adlai Nortye Ltd. American Depositary Shares. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Adlai Nortye Ltd. American Depositary Shares. Coverage tracks Adlai Nortye Ltd. American Depositary Shares within Biotechnology (Healthcare). Press releases and market coverage, newest first.